UCB’s Iram Hasan, Senior Manager, Regulatory Affairs, understands the importance of being flexible and attributes the milestones in her career path to this mentality. Read more from Iram on how keeping an open mind led her to launching UCB’s first PharmD fellowship program in Global Regulatory Affairs (GRA).

UCB is committed to investing in STEM education across the U.S. because we recognize the important role of the biopharmaceutical industry to inspire and develop a sustainable and diverse STEM workforce now and in the future. With this, we also know there are many challenges teachers and students may face when developing STEM programs, especially during a pandemic. As such, UCB has looked for different approaches to expand our investment to better support them. 

As UCB continues to grow as a global company, the diversity and inclusivity of the culture continues to expand as well by creating new opportunities of connection both within and beyond UCB’s employee community. In commemoration of Hispanic Heritage Month, UCB is proud to offer a new employee resource group (ERG), RAIZ, dedicated to the many Hispanic and Latino UCB colleagues. 

As a Senior Principal Data Scientist, Yuan Wang, PhD, uses her strength for uniting different people in her field to drive innovation at UCB, and encourages her team to value the importance of diversity in collaboration. Read her story. 

Last week, UCB researchers from across the country gathered virtually for the PhRMA Researcher Fly-In where more than 70 industry researchers engaged with Members of Congress. Read their stories. 

UCB and Aetion announced a new agreement to advance UCB’s use of real-world evidence (RWE) using rapid and robust analytics. 

At UCB, we know we need diverse perspectives and experiences to do our best work. Passionate scientists like Nikita, who exemplify our vision to embrace new knowledge and to work to discover meaningful solutions for patients, are a driving force for innovation at UCB. Stay tuned over the next few weeks to read stories from UCB women researchers who are pushing the boundaries of science. 

• The U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) have accepted marketing application submissions for bimekizumab for the treatment of adults with moderate to severe plaque psoriasis
• This accepted submission is supported by a robust data package including three Phase 3 studies which demonstrate superiority of bimekizumab to placebo, Stelara® (ustekinumab) and Humira® (adalimumab) in achieving skin clearance at week 16

•    Phase II data demonstrated a favorable safety profile across all reported dose groups and clinically meaningful platelet count increases with meaningful decreases in IgG concentration 

UCB is committed to investing in the future generation of leaders. Established in 2017, the UCB Global Regulatory Affairs (GRA) PharmD Fellowship Program, a collaboration with the Industry Pharmacists Organization (IPhO), was designed to provide PharmD graduates with the opportunity to learn and experience all aspects of regulatory affairs under the mentorship of experienced preceptors.